RCS - Biotech Growth Trust - Edison issues review on The Biotech Growth Trust

Biotech Growth TrustAnnouncement

04/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220404:nRSD9413Ga&default-theme=true

RNS Number : 9413G  Biotech Growth Trust PLC (The)  04 April 2022

 

London, UK, 4 April 2022

 

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) is managed by Geoff Hsu at healthcare
specialist OrbiMed Capital, and benefits from OrbiMed's presence in 11 offices
across the globe. While the trust has had a weak period of absolute and
relative performance over the last 12 months, the manager believes that the
focus on emerging biotech (smaller-cap) and emerging market biotech stocks is
the correct strategy; following this approach proved very successful for
BIOG's FY21 results. Investors are currently not focusing on the biotech
sector's strong fundamentals, and the sell-off since early-February 2021 may
have created a very attractive entry point for those willing to look beyond
the current cyclical/value stock market leadership.

 

Perhaps reflecting weakness in the biotech sector, BIOG's valuation has been
volatile since the middle of 2021. Its current 6.6% discount to cum-income NAV
compares with a range of a 3.3% premium to an 11.5% discount over the last 12
months. Over the last one, three, five and 10 years the trust's average
discounts are 2.5%, 4.3%, 5.0% and 4.6%, respectively.

Click here
(https://www.edisongroup.com/publication/manager-expects-a-reversal-of-recent-results/30689/?utm_campaign=EQS%20Press%20Releases&utm_source=EQS&utm_medium=Press%20Release)
to view the full report or here
(https://share.hsforms.com/1xWgTZ4FTQ7KIe9TkD-Gq6A3k1vq) to sign up to receive
research as it is published.

 

All reports published by Edison are available to download free of charge from
its website

www.edisongroup.com (http://www.edisongroup.com)

About Edison: Edison is a leading research and investor relations consultancy,
connecting listed companies to the widest pool of global investors. By
focusing on the volume and quality of investors reached - across institutions,
family offices, wealth managers and retail investors - Edison can create and
gauge intent to purchase, even in the darkest pools of capital, and then make
introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100
analysts covering every economic sector. Headquartered in London, Edison also
has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in
Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority
(https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN) .

Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
(mailto:investmenttrusts@edisongroup.com)

Sarah Godfrey +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
(mailto:investmenttrusts@edisongroup.com)

Learn more at www.edisongroup.com (http://www.edisongroup.com) and connect
with Edison on:

LinkedIn        www.linkedin.com/company/edison-group-/
(http://www.linkedin.com/company/edison-group-/)

Twitter           www.twitter.com/Edison_Inv_Res
(http://www.twitter.com/Edison_Inv_Res)

YouTube       www.youtube.com/edisonitv
(http://www.youtube.com/edisonitv)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAPLFEAPAEEA